Business Context and Reporting Period
Company: RXi Pharmaceuticals Corporation (Note: Input metadata referenced "Phio Pharmaceuticals," but the filing text identifies the registrant as RXi Pharmaceuticals Corporation).
Filing Type: Form 8-K (Current Report).
Reporting Date: August 14, 2018.
Period Covered: Results of operations for the quarter ended June 30, 2018.
Location: Marlborough, Massachusetts.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for the quarter ended June 30, 2018. The text does not provide specific numerical values for the following metrics:
- Revenue
- Net Profit/Loss
- Cash Flow
- Profit Margins
- Debt Levels
- Liquidity Position
Investors must refer to the attached Exhibit 99.1 (Press Release) for detailed financial data.
Material Changes
The filing text does not contain specific data regarding material changes in financial performance compared to the prior comparable period. It only confirms the reporting of results for the quarter ended June 30, 2018.
Guidance, Outlook, and Risks
Management Commentary: The report was signed by Geert Cauwenbergh, President, CEO, and acting CFO.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not treated as "filed" under Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated.
Guidance/Risks: No specific forward-looking guidance, risk factors, or contingencies are detailed in the text of this Form 8-K.
Investor Verification Checklist
- Verify the specific financial figures (revenue, cash burn, net loss) in the attached Exhibit 99.1 Press Release, as they are absent from this summary text.
- Confirm the company name discrepancy between the request metadata ("Phio Pharmaceuticals") and the filing ("RXi Pharmaceuticals Corporation").
- Review the press release for any updates on clinical trial progress or product development, which are typical drivers for this company's valuation.
- Check the company's cash runway and liquidity status in the full press release to assess solvency.